Company / Accounts Receivable
Vir Biotechnology, Inc. Accounts Receivable History
FY2020-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$773.1M
FY2021
5-year range
$773.1M / $773.1M
FY2020-FY2021
Trend
-
vs FY2020
Sector context
#22 of 113
Health Care
What the data says
Vir Biotechnology, Inc.'s accounts receivable of $773M is higher than 81% of companies in the Health Care sector (FY2021).
Based on SEC 10-K filings.
$773M in FY2021. Top quartile in the Health Care sector.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 19% in Health CareTop 19% of 113This company $773.1M Sector average $1.1B
▼
-32.0% below sector average
Key checks
Key Insights
- Ranks #22 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $773.1M | - |
| FY2020 | $0 | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
As of FY2021 · SEC 10-K · Updated Jun 30, 2026